An open-label, single-sequence study to investigate the effects of gastric acid suppression by Rabeprazole on the pharmacokinetics of BMS-986165 in healthy participants
Completed
- Conditions
- Psoriasissystemic lupus erythematosus and Crohn's disease.10003816
- Registration Number
- NL-OMON47975
- Lead Sponsor
- BritsolMyers Squibb Research and Development
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
- Healthy male and female subjects
- Age of 18 to 50 years (inclusive)
- BMI of 18.0 to 32.0 kg/m2 (inclusive)
Exclusion Criteria
Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. Donation of blood
to a blood bank or in a clinical study (except a screening visit) within 4
weeks of study drug administration (within 2 weeks for plasma only). Blood
transfusion within 4 weeks of study drug administration.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>PK parameters in healthy participants administered BMS-986165 alone (reference)<br /><br>versus in combination with rabeprazole (test):<br /><br>- BMS-986165: Cmax, AUC(0-T), AUC(INF)</p><br>
- Secondary Outcome Measures
Name Time Method <p>PK of BMS-986165 administered alone (reference) versus in combination with<br /><br>rabeprazole (test)<br /><br>- BMS-986165: Tmax, T-Half<br /><br>- Total active circulating species: Cmax, AUC(0-T), AUC(INF)</p><br>